199 related articles for article (PubMed ID: 17145229)
1. Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus.
Hernandez TL; Capell WH; Wolfe P; Gerard LA; Eckel RH
Am J Cardiol; 2006 Dec; 98(12):1656-9. PubMed ID: 17145229
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C.
Miller M; Dobs A; Yuan Z; Battisti WP; Borisute H; Palmisano J
Curr Med Res Opin; 2004 Jul; 20(7):1087-94. PubMed ID: 15265253
[TBL] [Abstract][Full Text] [Related]
3. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
Bays HE; Davidson M; Jones MR; Abby SL
Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
[TBL] [Abstract][Full Text] [Related]
4. Strong suppression of high-sensitivity C-reactive protein level and its mediated pro-atherosclerotic effects with simvastatin: in vivo and in vitro studies.
Yip HK; Sun CK; Chang LT; Wu CJ; Chua S; Fu M
Int J Cardiol; 2007 Oct; 121(3):253-60. PubMed ID: 17196684
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events.
Michelena HI; Osorio LA; Citkowitz E
Int J Cardiol; 2005 May; 101(1):111-4. PubMed ID: 15860392
[TBL] [Abstract][Full Text] [Related]
6. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
Malmström RE; Settergren M; Böhm F; Pernow J; Hjemdahl P
Thromb Haemost; 2009 Jan; 101(1):157-64. PubMed ID: 19132203
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
Ansell BJ; Navab M; Hama S; Kamranpour N; Fonarow G; Hough G; Rahmani S; Mottahedeh R; Dave R; Reddy ST; Fogelman AM
Circulation; 2003 Dec; 108(22):2751-6. PubMed ID: 14638544
[TBL] [Abstract][Full Text] [Related]
8. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients.
Panichi V; Paoletti S; Mantuano E; Manca-Rizza G; Filippi C; Santi S; Taccola D; Donadio C; Tramonti G; Innocenti M; Casto G; Consani C; Sbragia G; Franzoni F; Galetta F; Panicucci E; Barsotti G
Nephrol Dial Transplant; 2006 Feb; 21(2):337-44. PubMed ID: 16249194
[TBL] [Abstract][Full Text] [Related]
10. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
11. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
12. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
[TBL] [Abstract][Full Text] [Related]
14. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
16. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
17. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial.
Zubaid M; Shakir DK; Bazargani N; Binbrek A; Gopal R; Al-Tamimi O; Bakir S
J Cardiovasc Med (Hagerstown); 2008 Jul; 9(7):688-93. PubMed ID: 18545068
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients.
Yamada S; Yanagawa T; Sasamoto K; Araki A; Miyao M; Yamanouchi T
Metabolism; 2006 Jan; 55(1):67-71. PubMed ID: 16324921
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
Burmeister JE; Miltersteiner DR; Campos BM
J Nephrol; 2009; 22(1):83-9. PubMed ID: 19229822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
